Navigation Links
Metamark and HistoRx Announce Licensing Agreement for AQUA® Technology
Date:12/20/2010

CAMBRIDGE, Mass. and BRANFORD, Conn., Dec. 20, 2010 /PRNewswire/ -- Metamark Genetics, Inc., a privately held oncology-focused molecular diagnostics company, and HistoRx, Inc., a diagnostics company developing tissue-based diagnostic solutions to advance individualized patient care, today announced a multi-year licensing agreement.  HistoRx has granted Metamark a worldwide license to the AQUA technology for the clinical commercialization of Metamark's proprietary MetamarkDx™ Prognostic Assays.  

For several years, Metamark has engaged HistoRx for research work in support of Metamark diagnostic assays based on HistoRx's proprietary AQUA technology.   The two companies have been working to achieve key validation milestones prior to finalizing this agreement.  Metamark's proprietary MetamarkDx Prognostic Assays will evaluate the molecular profile of an individual patient's tumor through quantitative expression analysis of Metamark's proprietary Prognosis Determinants™. This will enable the identification of those early stage cancers that are genetically hardwired for lethal spread, as well as those that are less aggressive, thus arming physicians with critical insight to be able to guide their patients towards more personalized treatment strategies.

The licensed portfolio includes assays performed using HistoRx's proprietary technology for analysis of fluorescent immunohistochemistry, enabling quantitative assessment of specific biomarkers for patients with certain solid tumors.  

"We are delighted to be working with HistoRx and are eager to develop and validate clinical diagnostics for key biomarkers using AQUA technology, and to ultimately commercialize them for the benefit of patients around the world," said Mark Straley, President and Chief Executive Officer of Metamark.  "Metamark's powerful Prognosis Determinants™ technology, and the multimarker assay panels developed from it, requires objective and reproducible quantitative measurement of protein biomarkers – something specifically enabled by HistoRx's AQUA technology."

"Metamark's unique approach to investigating the drivers of cancer development and metastasis has tremendous potential for changing the face of these diseases," said Rana K. Gupta, CEO of HistoRx.  "We are pleased to see the ways that AQUA® technology and the collaboration between HistoRx scientists and the Metamark team have led to significant progress towards this goal."

About Metamark Genetics, Inc.

Metamark is a privately held oncology company focused on the development of function-based prognostic assays for early staged cancers. The MetamarkDx Prognostic Assays under development are based on Metamark's proprietary Prognosis Determinants, genes discovered through leading edge cancer research and demonstrated to play a causal role in promoting tumor progression and spread. For further information, please visit the company's website at www.metamarkgenetics.com.

About HistoRx, Inc.

HistoRx, Inc. is a leading developer of tissue-based diagnostic solutions to advance individualized patient care. The company's products and services are based on proprietary analysis of tissue biomarkers using AQUA technology. AQUA technology is the only platform capable of precisely measuring protein biomarker concentration with sub-cellular resolution in tissue sections, enabling fully objective, standardized, reproducible, and automated analysis to guide drug development and therapeutic decision-making. HistoRx is commercializing a pipeline of proprietary diagnostic products targeting improved treatment decision-making and patient outcomes in cancer care. For more information, please visit www.historx.com.


'/>"/>
SOURCE HistoRx, Inc.; Metamark Genetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Metamark Genetics, Inc. Announces New Chief Executive Officer
2. Metamark Genetics, Inc. Announces New Chief Scientific Officer
3. Jack Davis, Diagnostics Industry Executive, Joins the HistoRx Board of Directors
4. Heiner Dreismann, Ph.D., Former President of Roche Molecular Systems, Joins the HistoRx Board of Directors
5. HistoRx Receives Key Patent on Application of AQUA(R) Technology to Personalized Medicine
6. Genoptix and HistoRx Announce Licensing Agreement for AQUA(R) Technology
7. HistoRx Names Dick Carroll, Ph.D. as VP of Clinical Research
8. InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe
9. Sequenom Announces Publication Acceptance of Manuscript From Trisomy 21 R&D Verification Study
10. Talecris Biotherapeutics Announces Jury Verdict in Contract Dispute
11. China Cord Blood Corporation Announces Completion of Warrant Exchange
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... ... Scientists at the University of Athens say they have evidence that the variety ... that could lead to one good one. Surviving Mesothelioma has just posted an article ... team evaluated 98 mesothelioma patients who got a second kind of drug ...
(Date:5/25/2016)... ... May 25, 2016 , ... Biohaven Pharmaceutical Holding Company Ltd. ... the company’s orphan drug designation request covering BHV-4157 for the treatment of Spinocerebellar ... FDA. , Spinocerebellar ataxia is a rare, debilitating neurodegenerative disorder that is ...
(Date:5/24/2016)... ... May 24, 2016 , ... Last week, Callan Capital, ... executives and entrepreneurs, held The Future of San Diego Life Science event at the ... life science community attended the event with speakers Dr. Rich Heyman, former CEO of ...
(Date:5/23/2016)... ... May 23, 2016 , ... PrecisionAg® Media has released ... and Beyond. The paper outlines the key trends that are creating both opportunities ... witnessed a lot of highs and lows as the precision agriculture market has ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):